Company: HSDTW
Filing Date: 2025-03-25
Form Type: S-3/A
Source: 0001104659-25-027793
Chunk: 9

Company: Solana Co
Filing Date: 2025-03-25
Form: S-3/A
Chunk 9
---
 and eligible for trading on Nasdaq pending the ultimate conclusion of the hearing process.

If our common stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our common stock and could harm our business and future prospects. In addition, we believe that, if our common stock is delisted, our stockholders would likely find it more difficult to obtain accurate quotations as to the price of the common stock and it may be more difficult for stockholders to buy or sell our common stock at competitive market prices, or at all.

#### Our Corporate Information
We are incorporated in the state of Delaware under the name Helius Medical Technologies, Inc. Our principal executive offices are located at 642 Newtown Yardley Road, Suite 100, Newtown, Pennsylvania 18940, and our telephone number is (215) 944-6100. Our website address is www.heliusmedical.com. We have included our website address in this prospectus solely as an inactive textual reference. The information on, or that can be accessed through, our website is not part of this prospectus, and you should not rely on any such information in making the decision whether to purchase securities.

<div align='center'>4</div>

TABLE OF CONTENTS

### THE OFFERING
Securities

6,213,888 shares of our common stock, issuable upon the exercise of Series C Warrants and Series D Warrants.

Terms of the offering

The selling stockholders will each determine when and how they will sell the Securities offered in this prospectus, as described in the “Plan of Distribution.”

Terms of the Series C Warrants and Series D Warrants

Each Series C Warrant entitles the holder to purchase one share of common stock, subject to any adjustments, at an exercise price of $0.751 per share. The Series C Warrants will expire five years from the date of stockholder approval.

Each Series D Warrant entitles the holder to purchase one share of common stock, subject to any adjustments, at an exercise price of $0.751 per share. The Series D Warrants will expire two years from the date of stockholder approval.

Use of proceeds

We will not receive any proceeds from the sale of the Securities by the selling stockholders in this offering. See “Use of Proceeds.”

Risk factors

See the section under the heading “Risk Factors” in